Original Source(s)
Related Content
Phoenix Children’s Joins First Controlled Clinical Trial of Genetic Therapy for Dravet Syndrome
The first controlled phase 3 trial of a genetic therapy for Dravet syndrome is now underway – with Phoenix Children's as one of 28 sites nationwide.
Redefining Fontan Care: The Socio-Economic Impact of SVHD on Families
Survey results reveal the long-term socio-economic and psychological impacts of single ventricle congenital heart disease (SVHD) on families. See how cardiologists Deepti Bhat, MD, and Naim Duran, MD, contributors to this research, are using findings to transform Fontan Clinic care at Phoenix Children’s.
